Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

38

Revenue 2017

Imbruvica

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Imbruvica was produced by Johnson & Johnson.

Imbruvica gains expanded use in Europe

Imbruvica gains expanded use in Europe Rival Calquence receives accelerated review in US. AbbVie and Janssen’s Imbruvica (ibrutinib) has received approval from the European Commission (EC) for two expanded variations to broaden the use of the ... Imbruvica has experienced some heated

AbbVie to acquire Allergan for $63bn

AbbVie to acquire Allergan for $63bn Analysts have not been overly impressed with the bolt-on acquisitions AbbVie has paid for in recent years; the $21bn it spent acquiring Pharmacyclics and its lymphoma treatment Imbruvica was seen

AZ’s Calquence threatens Imbruvica with new leukaemia data

AZ’s Calquence threatens Imbruvica with new leukaemia data in its market battle with AbbVie/Johnson &Johnson’s Imbruvica. ... That could give Calquence a leg-up as it tries to make inroads against Imbruvica (ibrutinib), which is already approved as a first- and second-line therapy for CLL and a

MorphoSys eyes 2020 launch for lymphoma CAR-T challenger

MorphoSys eyes 2020 launch for lymphoma CAR-T challenger lymphocytic lymphoma (SLL) who have failed or become intolerant to prior treatment with Johnson &Johnson’s Imbruvica (ibrutinib).

Venclexta plus Gazyva approval adds to non-chemo options in CLL

Venclexta plus Gazyva approval adds to non-chemo options in CLL Roche’s marketing partner AbbVie has a stake in a direct rival, Imbruvica, which it co-markets with J&J. ... In January, Imbruvica gained approval in first line treatment in combination with Gazyva, making it the first non-chemo combination in this

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics